Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Next Previous
Trial Profile

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Erythrodermic psoriasis; Generalised pustular psoriasis
  • Focus Therapeutic Use
  • Acronyms UNCOVER-J2
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 29 Dec 2021 Results assessing the safety and efficacy of ixekizumab administered Q2W beyond Week 12 until Week 20 in patients with GPP and EP published in the Dermatology and Therapy
  • 07 Aug 2020 Status changed from active, no longer recruiting to completed.
  • 16 Jun 2020 Planned End Date changed from 30 Oct 2020 to 22 Jul 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top